Monoclonal antibodies for treating COVID-19
Andrea Pallotta, ChungYun Kim, Steven M. Gordon, Alice Kim
Abstract
Bamlanivimab and casirivimab-imdevimab are novel virus-neutralizing monoclonal antibodies authorized to treat mild to moderate COVID-19 in outpatients at risk for progression to severe disease. Treatment early in the disease may show efficacy in reducing progression to severe disease, although safety and efficacy data are limited. They are not authorized for hospitalized patients with more advanced disease.
Topics & Concepts
MedicineMonoclonal antibodyCoronavirus disease 2019 (COVID-19)DiseaseAntibody2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyMonoclonalImmunologyInternal medicineInfectious disease (medical specialty)OutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmunodeficiency and Autoimmune Disorders